Analyst Price Target is GBX 7.20
▲ +700.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for MGC Pharmaceuticals in the last 3 months. The average price target is GBX 7.20, with a high forecast of GBX 0 and a low forecast of GBX 0. The average price target represents a 700.00% upside from the last price of GBX 0.90.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in MGC Pharmaceuticals.
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia. It has research and development agreement with Royal Melbourne Institute of Technology and the University of Notre Dame; and collaboration agreement with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.